October 31, 2020
Rose
Gilead Sciences said Wednesday that remdesivir, which has been authorized for emergency use since the spring, brought in $873 million in revenues so far this year.
from Health https://ift.tt/31QSZsg
October 31, 2020
Rose
Health, Health - The New York Times
No comments
Related Posts:
Moderna and U.S. at Odds Over Vaccine Patent Rights- A Doctor Asks Two Strange Questions That Reveal a Mysterious Disease
- States Sue U.S. Over Vaccine Mandate for Health Care Workers.
- What Is HIIT and How Does the Training Benefit Your Health?
- Pfizer Asks F.D.A. to Expand Booster Eligibility to All Adults
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment